A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib.
作者信息
Pietrobono Silvia, Melisi Davide
机构信息
Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, Verona, Italy.
Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, Experimental Cancer Medicine Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
出版信息
Cell Mol Gastroenterol Hepatol. 2021;12(3):1151-1152. doi: 10.1016/j.jcmgh.2021.06.005. Epub 2021 Jun 25.
Abstract
摘要
相似文献
1
A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib.
Cell Mol Gastroenterol Hepatol. 2021;12(3):1151-1152. doi: 10.1016/j.jcmgh.2021.06.005. Epub 2021 Jun 25.
2
Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.阻断膜联蛋白 A3 可增强索拉非尼和瑞戈非尼对肝细胞癌的敏感性。
J Hepatol. 2018 Oct;69(4):826-839. doi: 10.1016/j.jhep.2018.05.034. Epub 2018 Jun 7.
3
Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity.索拉非尼诱导的超敏反应后使用瑞戈非尼成功治疗肝细胞癌
Intern Med. 2019 Oct 1;58(19):2803-2808. doi: 10.2169/internalmedicine.2812-19. Epub 2019 Jun 27.
4
Sorafenib and Lenvatinib as first-line treatment of hepatocellular carcinoma: A still controversial comparison.索拉非尼和仑伐替尼作为肝细胞癌的一线治疗：一项仍具争议的比较。
Liver Int. 2021 Jun;41(6):1432. doi: 10.1111/liv.14853. Epub 2021 Apr 19.
5
[Hepatectomy vs. sorafenib in advanced hepatocellular cancer].
Chirurgie (Heidelb). 2022 Jun;93(6):604-605. doi: 10.1007/s00104-022-01657-0. Epub 2022 May 19.
6
[Experience and future prospect of hepatocellular carcinoma treatment by sorafenib].索拉非尼治疗肝细胞癌的经验与未来展望
Nihon Shokakibyo Gakkai Zasshi. 2019;116(1):18-27. doi: 10.11405/nisshoshi.116.18.
7
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?肝细胞癌与索拉非尼：存在过多的耐药机制？
Gut. 2013 Dec;62(12):1674-5. doi: 10.1136/gutjnl-2013-304564. Epub 2013 Mar 12.
8
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.晚期肝细胞癌系统治疗的药物遗传学。
World J Gastroenterol. 2019 Aug 7;25(29):3870-3896. doi: 10.3748/wjg.v25.i29.3870.
9
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.索拉非尼耐药的潜在分子、细胞及微环境机制在肝细胞癌中的研究。
Cancer Lett. 2015 Oct 10;367(1):1-11. doi: 10.1016/j.canlet.2015.06.019. Epub 2015 Jul 10.
10
Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma.自噬在肝癌索拉非尼耐药中的多重作用
Cell Physiol Biochem. 2017;44(2):716-727. doi: 10.1159/000485285. Epub 2017 Nov 23.
本文引用的文献
1
TAK1 signaling is a potential therapeutic target for pathological angiogenesis.TAK1信号通路是病理性血管生成的一个潜在治疗靶点。
Angiogenesis. 2021 Aug;24(3):453-470. doi: 10.1007/s10456-021-09787-5. Epub 2021 May 10.
2
TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.TAK1 是肝细胞癌的一个新靶点，促进索拉非尼耐药。
Cell Mol Gastroenterol Hepatol. 2021;12(3):1121-1143. doi: 10.1016/j.jcmgh.2021.04.016. Epub 2021 May 5.
3
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.血浆 IL8 是 TAK1 激活的生物标志物，可预测吉西他滨耐药性胰腺癌患者对纳米脂质体伊立替康的耐药性。
Clin Cancer Res. 2020 Sep 1;26(17):4661-4669. doi: 10.1158/1078-0432.CCR-20-0395. Epub 2020 Jun 12.
4
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
5
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
6
Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer.调控 TAK1 表达抑制胰腺癌中 YAP 和 TAZ 的致癌功能。
Mol Cancer Ther. 2020 Jan;19(1):247-257. doi: 10.1158/1535-7163.MCT-19-0270. Epub 2019 Sep 27.
7
TAK1 Prevents Endothelial Apoptosis and Maintains Vascular Integrity.TAK1 防止血管内皮细胞凋亡并维持血管完整性。
Dev Cell. 2019 Jan 28;48(2):151-166.e7. doi: 10.1016/j.devcel.2018.12.002. Epub 2019 Jan 10.
8
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy.针对化疗耐药性：MAP3K7 作为癌症治疗靶点的新兴作用。
Drug Resist Updat. 2017 Nov;33-35:36-42. doi: 10.1016/j.drup.2017.10.004. Epub 2017 Nov 3.
9
TAK1 kinase signaling regulates embryonic angiogenesis by modulating endothelial cell survival and migration.TAK1 激酶信号通过调节内皮细胞存活和迁移来调节胚胎血管生成。
Blood. 2012 Nov 1;120(18):3846-57. doi: 10.1182/blood-2012-03-416198. Epub 2012 Sep 12.
10
The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation.E3 连接酶 Itch 和去泛素化酶 Cyld 共同调节 Tak1 和炎症。
Nat Immunol. 2011 Nov 6;12(12):1176-83. doi: 10.1038/ni.2157.
Zotero 插件